VEGFA and neoplasm: The promising therapeutic role of VEGF inhibitors, particularly bevacizumab, is the subject of ongoing research, as these agents not only inhibit angiogenesis and disrupt tumor vascularization but also impact CAFs, which contribute to the TME (Zhang et al., 2024).